← All indications
Immunoglobulin Light-chain Amyloidosis
A nonproliferative disorder of PLASMA CELLS characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.
Drugs by status
Phase 4 trials (2)
Phase 3 trials (12)
Phase 2 trials (25)
- venetoclax
- bendamustine
- lenalidomide
- doxycycline
- doxorubicin
- etanercept
- idelalisib
- ixazomib
- neod001
- Isatuximab
- siltuximab
- cyclosporine
- mycophenolate
- allogeneic lymphocytes
- autologous mononuclear stem cell
- fludarabine
- cisplatin
- etoposide
- pomalidomide
- belantamab mafodotin
- mrna-1273
- Elranatamab
- teclistamab
- zn-d5
- equecabtagene autoleucel
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (34)
- Spectrum Pharmaceuticals
- Celgene
- Cephalon
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- GlaxoSmithKline
- Oncopeptides AB
- PETHEMA Foundation
- Cancer and Leukemia Group B (CALGB)
- University of London
- Cornell University
- Eastern Cooperative Oncology Group
- University of Washington
- Herbert Irving Comprehensive Cancer Center
- Hoosier Cancer Research Network
- Medical College of Wisconsin
- Southwest Oncology Group
- Tufts University
- University of Heidelberg
- University of Iowa
- University of Rochester
- Wayne State University
- Columbia University
- University of Chicago
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- Prothena Biosciences Inc
- Pharmaceutical Research Associates, Inc. (PRA)
- Janssen Pharmaceutica NV
- University of Texas at Houston
- +4 more
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (6)